Cargando…

Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach

BACKGROUND: Many trials of amyloid‐modulating agents fail to improve cognitive outcome in Alzheimer's disease despite substantial reduction of amyloid β levels. METHODS: We applied a mechanism‐based Quantitative Systems Pharmacology model exploring the pharmacodynamic interactions of apolipopro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geerts, Hugo, Spiros, Athan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Featured Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983876/ https://www.ncbi.nlm.nih.gov/pubmed/32255562 http://dx.doi.org/10.1002/alz.12082

Ejemplares similares

Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model
por: Geerts, Hugo, et al.
Publicado: (2018)

Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology
por: Geerts, Hugo, et al.
Publicado: (2015)

F189. PERSONALIZED MEDICINE: ESTIMATING THE IMPACT OF GENOTYPES ON ANTIPSYCHOTIC EFFICACY USING A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH
por: Geerts, Hugo, et al.
Publicado: (2018)

Toward Predicting Impact of Common Genetic Variants on Schizophrenia Clinical Responses With Antipsychotics: A Quantitative System Pharmacology Study
por: Spiros, Athan, et al.
Publicado: (2021)

A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson’s Disease
por: Roberts, Patrick, et al.
Publicado: (2016)

A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance
por: Spiros, Athan, et al.
Publicado: (2014)

S221. QUANTITATIVE SYSTEMS PHARMACOLOGY AS AN ALTERNATIVE TO CHLORPROMAZINE EQUIVALENTS: PREDICTIVE VALIDATION FROM A CRIS DATABASE EXPERIMENT
por: Geerts, Hugo, et al.
Publicado: (2018)

A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development
por: Spiros, Athan, et al.
Publicado: (2012)

A biophysically realistic computer model of Alzheimer pathology to guide the development of symptomatic drugs
por: Roberts, Patrick D, et al.
Publicado: (2012)

Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action
por: Roberts, Patrick D, et al.
Publicado: (2012)

A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer’s disease
por: Geerts, Hugo, et al.
Publicado: (2013)

Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
por: Lopes Alves, Isadora, et al.
Publicado: (2020)

A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease
por: Geerts, Hugo, et al.
Publicado: (2023)

A Quantitative System Pharmacology Computer Model for Cognitive Deficits in Schizophrenia
por: Geerts, H, et al.
Publicado: (2013)

Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse
por: Spiros, Athan, et al.
Publicado: (2010)

Ganglion cell layer thinning in prodromal Alzheimer's disease defined by amyloid PET
por: López-de-Eguileta, Alicia, et al.
Publicado: (2019)

Civility Mentor: A Virtual Learning Experience
por: Clark, Cynthia M., et al.
Publicado: (2020)

UB-311, a novel UBITh(®) amyloid β peptide vaccine for mild Alzheimer's disease
por: Wang, Chang Yi, et al.
Publicado: (2017)

Virtual reality-based cognitive-motor training for middle-aged adults at high Alzheimer's disease risk: A randomized controlled trial
por: Doniger, Glen M., et al.
Publicado: (2018)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

Moderate- to high-intensity exercise does not modify cortical β-amyloid in Alzheimer's disease
por: Frederiksen, Kristian S., et al.
Publicado: (2019)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

APP accumulates with presynaptic proteins around amyloid plaques: A role for presynaptic mechanisms in Alzheimer's disease?
por: Jordà‐Siquier, Tomàs, et al.
Publicado: (2022)

Development of Written Materials for Participants in an Alzheimer's Disease and Related Dementias Screening Trial
por: Head, Katharine J, et al.
Publicado: (2022)

Electives: virtual, domestic and abroad
por: Ahmed, Tasnim Aniqa, et al.
Publicado: (2022)

Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
por: Lin, Lin, et al.
Publicado: (2022)

Normal cerebrospinal fluid concentrations of PDGFRβ in patients with cerebral amyloid angiopathy and Alzheimer's disease
por: De Kort, Anna M., et al.
Publicado: (2021)

Going Virtual: Redesigning the Interview Experience
por: Deitte, Lori A., et al.
Publicado: (2021)

Conducting virtual meetings during the pandemic
por: Large, Alison
Publicado: (2021)

Virtual Reality Simulation in Nursing and Midwifery Education: A Usability Study
por: Saab, Mohamad M., et al.
Publicado: (2023)

Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial
por: Fruijtier, Agnetha D., et al.
Publicado: (2022)

Virtual visits in palliative care: about time or against the grain?
por: Hawkins, Joseph Paul, et al.
Publicado: (2020)

Prediction of Efficacy of Vabicaserin, a 5-HT(2C) Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model
por: Liu, J, et al.
Publicado: (2014)

“Won’t You Be My Doctor?”: Four Keys to a Satisfying Relationship in an Increasingly Virtual World
por: Frankel, Richard M, et al.
Publicado: (2020)

Cerebral amyloid‐β load is associated with neurodegeneration and gliosis: Mediation by p‐tau and interactions with risk factors early in the Alzheimer's continuum
por: Salvadó, Gemma, et al.
Publicado: (2021)

Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates
por: Ramakrishnan, Vidya, et al.
Publicado: (2022)

A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study
por: Villemagne, Victor L., et al.
Publicado: (2017)

NGP 555, a γ-secretase modulator, lowers the amyloid biomarker, Aβ(42,) in cerebrospinal fluid while preventing Alzheimer's disease cognitive decline in rodents
por: Kounnas, Maria Z., et al.
Publicado: (2016)

Enhancing Your Webside Manner: Optimizing Opportunities for Relationship-Centered Care in Virtual Visits
por: Modic, Mary Beth, et al.
Publicado: (2021)

The Heart and Medicine: Exploring the Interconnectedness of Cardiometabolic-related Concerns Through a Systems Biology Approach
por: Lamb, Joseph, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_d1ptdivc09i7cm5apv5agiiedf